A single trial readout just doubled a company’s market value in one session. Perplexity AI predicts the rerating continues, and the price prediction places Moderna at $180 to $240 by the end of 2026 with a $210 bullish base case.
The catalyst is Intismeran, the personalized mRNA cancer vaccine. Perplexity calls it the dominant valuation driver going forward. The Phase 3 INTerpath-001 melanoma trial met both primary endpoints. Recurrence-free survival and distant-metastasis-free survival both cleared alongside Keytruda.
That is the first late-stage validation of Moderna’s oncology platform. Perplexity frames it as potentially supporting a major melanoma-market opportunity.
Two near-term items support the case. FDA approval of mFLUSIVA adds a commercial product with revenue before oncology arrives. Even more, its reduced 2026 cost guidance improves cash-burn expectations. Together, they buy time for the oncology thesis to develop.
The risks are all data-dependent. Disappointing hazard ratios sit at the top of the list. Overall-survival data, pricing, and approval timing follow. Any of those could drive the stock toward $125 to $150.
Discover: Everyone’s Got a Take. Get Free $25 from Kalshi to Actually Trade Yours
Moderna (MRNA) Price Prediction: Perplexity AI Predicts One Melanoma Trial Rewrites The Entire Company
The daily chart shows a four-year collapse followed by a violent reversal. Moderna peaked near $170 in mid-2024 before entering a prolonged decline. That slide carried the price from $120 down to roughly $23 by late 2025. A base formed there through the autumn.
In early 2026, the recovery began, lifting prices toward $60 by March. July produced a run to $85 before a pullback. The latest session detonated. Price gapped from $116 to close at $174.38 on the trial news.
The close reads $174.38, up 176.97%, and $111.42. The daily range covered $114.46 to $176.66, with post-market at $180.17. Support sits at $150, then $120 and $85. Resistance appears at $180, then $210, and $240.
RSI reads 92.21 with its signal line far below at 52.98. That gap of nearly 40 points is extraordinary and reflects a one-day repricing rather than a trend. The oscillator is deeply overbought. Momentum is extreme, and readings at this level rarely persist without consolidation.
Perplexity’s base case sits 20% above this close. Detailed efficacy data and regulatory discussions are what decide whether the market holds this new level.
Discover: Your Market Calls Are Worth Something. Start with a free $25 on Kalshi
Moderna Just Showed What One Event Can Do. Kalshi Lets You Trade the Outcome Before the Repricing.
Moderna’s 177% move is the clearest reminder that markets often spend months waiting for one binary event to settle the argument.
Kalshi is built around that exact dynamic.
Instead of buying an asset and hoping the eventual market reaction matches your thesis, users can trade directly on real-world outcomes across economics, politics, crypto, technology, sports, and other event-driven markets. You decide what you think happens, see the probability other traders are assigning to it, and take a position before the outcome is known.
That can be especially useful when a stock has already repriced violently. Moderna buyers entering after the trial result are paying for information the market now knows. Event markets are about positioning while the uncertainty still exists.
Eligible new users who join Kalshi through CryptoNews can receive $25 through our referral link.
Get Your $25 on Kalshi
The post Perplexity AI Predicts Whether Moderna Stock Can Make Investors Rich in 2026 appeared first on Cryptonews.
